QUALITY OF LIFE AMONG ADULT PATIENTS WITH PSORIASIS

A study using data from the Malaysian Psoriasis Registry

Choong-Chor Chang¹, Felix Boon-bin Yap¹, Hemandas Belani Gangaram², Roshidah Baba¹

¹Department of Dermatology, Hospital Kuala Lumpur, Malaysia,
²Department of Dermatology, Prince Court Medical Centre, Malaysia
Introduction

- Psoriasis is an immune mediated multisystem disease which runs a chronic debilitating course.
- It causes profound physical and psychosocial impact, hence reducing the quality of life (QoL) of patients.
- Previous studies showed that the impact on QoL may be affected by various factors in addition to the extent and severity of lesions of psoriasis.
Objectives

1. To determine the QoL among adult patients with various clinical types of psoriasis in Malaysia

2. To investigate various sociodemographic and clinical factors affecting the QoL impairment in patients with psoriasis
Methodology

• Cross-sectional analysis
• Data from the Malaysian Psoriasis Registry
• Adult patients aged 18 years and above
• 16 dermatology centres in Malaysia
• Study period: October 2007 to December 2009
• Quality of life was evaluated using the Dermatology Life Quality Index (DLQI)
• Statistical analysis using SPSS® v12
  – Independent t-test / Mann Whitney U test
Patient characteristics

• A total of 3,554 adult psoriasis patients were included

• Gender:
  – Male 57.5%, female 42.5%

• Age:
  – Mean age: $46.1 \pm 15.3$ years
  – Age range: 18 to 97 years

• Ethnicity:
  – Malay 47.2%, Chinese 25.8%, Indian 17.4%, others 9.4%
Clinical characteristics

Clinical type of psoriasis
- Plaque: 87.9%
- Scalp: 2.1%
- Flexural: 0.5%
- Palmoplantar: 0.4%
- Guttate: 4.6%
- Pustular: 1.4%
- Erythrodermic: 3.0%

% body surface area involved
- < 2%: 35.0%
- 2 - 10%: 40.9%
- > 10 - 90%: 21.0%
- > 90%: 3.1%
Clinical characteristics

• Age of onset: mean 35.6 years (range 0 to 85)
  – below 40 years (type 1 psoriasis) 63.6%
  – 40 years and above (type 2 psoriasis) 36.4%

• Mean duration of psoriasis: 10.5 ± 9.9 years

• Psoriatic arthropathy present in 17.2%

• Psoriatic nail disease present in 62.5%

• Mean DLQI score: 8.50 ± 6.47
Degree of QoL impairment due to psoriasis

- 0 - 1 (No effect)
- 2 - 5 (Slight effect)
- 6 - 10 (Moderate effect)
- 11 - 20 (Very large effect)
- 21 - 30 (Extremely large effect)

Number of patients

Quality of life among adult patients with psoriasis: a study using data from the Malaysian Psoriasis Registry
Aspects of QoL affected by psoriasis

Percentage of patients

- Symptoms and feelings
- Daily activities
- Leisure
- Work and School
- Personal relationships
- Treatment

- Very much
- A lot
- A little
- Not at all
Weak inverse correlation between DLQI score and the age of patient (Spearman’s rho $r=-0.306$, $p<0.001$)
Quality of life among adult patients with psoriasis: a study using data from the Malaysian Psoriasis Registry

Relationship between DLQI score and duration of psoriasis

Correlation between DLQI score and the duration of psoriasis: Spearman’s rho $r=-0.063$, $p<0.001$
## Factors affecting QoL impairment

<table>
<thead>
<tr>
<th>Factor</th>
<th>Mean DLQI score</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>8.15</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Female</td>
<td>8.97</td>
<td></td>
</tr>
<tr>
<td><strong>Age of onset of psoriasis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Below 40 years</td>
<td>9.56</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>40 years and above</td>
<td>6.64</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical type</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plaque</td>
<td>8.47</td>
<td></td>
</tr>
<tr>
<td>Guttate</td>
<td>9.33</td>
<td></td>
</tr>
<tr>
<td>Pustular</td>
<td>9.25</td>
<td></td>
</tr>
<tr>
<td><strong>Erythrodermic</strong></td>
<td>11.45</td>
<td>Erythrodermic vs non-erythrodermic p&lt;0.001</td>
</tr>
<tr>
<td>Palmoplantar</td>
<td>5.53</td>
<td></td>
</tr>
<tr>
<td>Flexural</td>
<td>5.00</td>
<td></td>
</tr>
<tr>
<td>Scalp only</td>
<td>6.11</td>
<td></td>
</tr>
<tr>
<td><strong>Extent of psoriasis (% of body surface area involved)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 10%</td>
<td>7.29</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>&gt; 10%</td>
<td>11.40</td>
<td></td>
</tr>
</tbody>
</table>
## Factors affecting QoL impairment

<table>
<thead>
<tr>
<th>Factor</th>
<th>Mean DLQI score</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scalp lesions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>7.06</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Moderate to severe</td>
<td>8.89</td>
<td></td>
</tr>
<tr>
<td><strong>Face lesions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>7.13</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Moderate to severe</td>
<td>10.03</td>
<td></td>
</tr>
<tr>
<td><strong>Psoriatic arthropathy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>8.14</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>10.19</td>
<td></td>
</tr>
<tr>
<td><strong>Psoriatic nail disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>8.12</td>
<td>p=0.011</td>
</tr>
<tr>
<td>Yes</td>
<td>8.70</td>
<td></td>
</tr>
<tr>
<td><strong>Any comorbidities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>9.17</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>7.54</td>
<td></td>
</tr>
</tbody>
</table>
Discussion

• Assessment of QoL is a patient-oriented means of measuring disease severity and impact

• QoL measure is increasingly being used in guiding clinical management decisions and evaluating efficacy of treatment

• Dermatology Life Quality Index (DLQI) which consists of a patient-administered 10-item questionnaire, is a well validated, practical and easy to use dermatology-specific instrument
Discussion

• Mean DLQI score of psoriasis patients in this study was similar to those reported in previous studies in other countries

<table>
<thead>
<tr>
<th>Studies of QoL in psoriasis</th>
<th>N</th>
<th>Mean DLQI score</th>
</tr>
</thead>
<tbody>
<tr>
<td>This study (Malaysia)</td>
<td>3,554</td>
<td>8.5 ± 6.5</td>
</tr>
<tr>
<td>Schoffski, 2007 (Germany)</td>
<td>184</td>
<td>10.6</td>
</tr>
<tr>
<td>Azzotti, 2003 (Italy)</td>
<td>758</td>
<td>8.7 ± 6.0</td>
</tr>
<tr>
<td>Finlay, 1994 (Cardiff, UK)</td>
<td>52</td>
<td>8.9 ± 6.3</td>
</tr>
</tbody>
</table>

• QoL impairment due to psoriasis is comparable to other common chronic skin diseases

<table>
<thead>
<tr>
<th>Skin Disease</th>
<th>Mean DLQI score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic eczema*</td>
<td>11.0</td>
</tr>
<tr>
<td>Psoriasis (this study)</td>
<td>8.5</td>
</tr>
<tr>
<td>Chronic urticaria*</td>
<td>8.4</td>
</tr>
<tr>
<td>Acne vulgaris#</td>
<td>4.1</td>
</tr>
<tr>
<td>Vitiligo*</td>
<td>3.5</td>
</tr>
</tbody>
</table>

#Yap FBB 2010 (Unpublished)
Discussion

- In this study, 60% of patients had DLQI score of >5 indicating moderate to severe QoL impairment.
- The most severely affected aspect of DLQI was “symptoms and feelings”, followed by “daily activities”, “leisure” and “treatment”.
- Similar to most previous studies, female patients had slightly higher impact of QoL.
- Older patients and those who had longer duration of disease had less QoL impairment probably due to improved coping skills and greater acceptance.
Discussion

• Patients who had earlier disease onset (type 1 psoriasis) tend to have more severe disease and greater QoL impairment

• Significantly worse QoL was found in patients who had erythrodermic psoriasis, larger extent of body surface involvement (>10%), psoriatic arthropathy or nail disease

• Pustular psoriasis, though often acutely severe, did not seem to cause much more QoL impairment

• Having moderate to severe lesions on the scalp or face was also associated with a worse QoL most likely linked to cosmetic disfigurement

• Presence of comorbidities did not seem to have additional impact on QoL
Conclusion

- The impact of psoriasis on QoL among adult Malaysian psoriasis patients is affected by various demographic and clinical factors.

- Hence, in addition to disease severity measure, assessment of QoL is essential in providing individualised optimal therapy for patients with psoriasis.
Strengths & Limitations

Strengths:

– Large sample size
– Registry data include entire range of patients
– Less selection bias

Limitations:

– Potential confounders and interactions among variables were not studied
– Some important factors might not have been included
– Limitations of QoL instrument used: DLQI may not capture certain aspects of QoL
Acknowledgement

We would like to thank the following for their contribution and support:

- The Director General of Health, Ministry of Health, Malaysia
- Patients, doctors and staff of all the participating dermatologic centres
- Clinical Research Centre, Ministry of Health, Malaysia
- Ms Noor Addillah bt Shueef, Registry Manager of the National Dermatology Registry
- Ms Premaa Supramaniam, Statistician of the Clinical Research Centre, Ministry of Health, Malaysia
- Professor A. Y. Finlay (Cardiff, UK) for granting permission to use the DLQI

References


Conflict of interest: None declared